original clinical study Purpose: to report the occurrence of fibrovascular proliferation (FVP) in the retina in von Hippel-lindau (VHl) patients and its association with prior treatment.
V
on Hippel-lindau (VHl) syndrome is an autosomal-dominant, multisystem cancer syndrome caused by a germline mutation in the VHl gene located on the short arm of chromosome 3.
1 the VHl gene encodes a tumor suppressor protein, the VHl protein (pVHl), which binds with elongin c, elongin B, and cul2 to form a protein complex. this protein complex is responsible for the ubiquitination of hypoxia-inducible factors (HiFs). 2 in the absence of pVHl, HiFs accumulate with subsequent overproduction of vascular endothelial growth factor, leading to abnormal angiogenesis and hemangioblastoma formation. retinal capillary hemangioblastoma (rcH) is the hallmark ocular lesion of the syndrome. classically, rcH is described as a raised, reddish, rounded, vascular lesion with dilated feeder and draining vessels that affects either the peripheral retina or, less commonly, the optic disc and the juxtapapillary region. 4, 5 other than the classically described rcH, an uncommon retinal vascular proliferative lesion has been reported and termed retinal vascular hamartomas, 6 We had noted that retinal fibrovascularization could occur in the posterior pole and in the periphery; therefore, in an attempt to clearly characterize these fibrovascular lesions, we searched the charts of VHl patients over the past 10 years and reviewed the available fundus photographs.
materials and methods
this is a retrospective study of patients with VHl disease to identify those with rcH who had retinal fibrovascular proliferation (FVP). the study was initiated after approval of the Mayo institutional review Board. Patients' records over the past 10 years at the Mayo clinic, rochester, Minnesota, were reviewed using the advanced cohort Explorer, a clinical data repository. the inquiry was conducted using the search terms "other congenital hamartoses not elsewhere classified including VHl (code: 759.6)" and "hemangioma of retina (code: 228.03)." statistical analysis was performed using χ 2 test, and a P value of 0.05 or less was regarded as statistically significant. the inquiry yielded 895 patients whose records were reviewed, identifying 124 patients with a preliminary diagnosis of VHl and excluding 771 patients who were not VHl patients. a second review of the 124 patients conducted by J.s.P. confirmed the diagnosis in 101 patients and excluded another 23 patients. the diagnosis and the reason for exclusion of these patients are shown in supplemental digital content 1 (http://www.apjo. org/apjo/figure/id/3). diagnosis of VHl was based on the presence of diagnostic clinical criteria, positive genetic testing of VHl gene mutation, or both. Briefly, diagnostic clinical criteria include a positive family history with a retinal hemangioblastoma, a central nervous system (cns) hemangioblastoma, renal cell carcinoma, or pheochromocytoma. in the absence of family history, there must be at least 2 retinal or cns hemangioblastomas, or a single retinal or cns hemangioblastoma, and a typical visceral tumor. patients had rcH. Fundus photos were available for 28 patients, and 15 patients were diagnosed as having fibrovascular proliferation (supplemental digital content 2; http://www.apjo.org/apjo/ figure/id/4). Fibrovascular proliferation was defined as peripheral FVP ( Fig. 1) if it occurred beyond the vascular arcades and was twice the distance between the fovea and the disc from the optic nerve, according to the definition for anatomic location of rcH used by Wong et al in 2007.
11 Because posterior pole fibrovascular proliferation (Fig. 2) is well-known in VHl but peripheral fibrovascular proliferation is not, eyes that had both posterior and peripheral fibrovascular proliferation were placed in the rarer peripheral fibrovascular proliferation group for statistical analysis.
results
We identified 28 patients whose color fundus photographs were available for analysis. Fundus fluorescein angiography, optical coherence tomography (oct) images, and detailed retinal drawings were also reviewed whenever available. of these, 15 patients were found to have fibrovascular proliferation (group a), whereas 13 patients showed no evidence of fibrovascular proliferation (group B). the mean age of patients in group a was 35 ± 11.3, which showed no statistically significant difference (P = 0.74) from that in group B (36.6 ± 13.8). there were 8 (53.3%) males and 7 (46.7%) females in group a, with 4 (30.8%) males and 9 (69.2%) females in group B (P = 0.03; table 1).
in group a, 80% of the patients had bilateral rcH (supplemental digital content 3; http://www.apjo.org/apjo/figure/id/5) compared with 46% in group B (supplemental digital content 4; http://www.apjo.org/apjo/figure/id/6; P = 0.003).
in group a, 27 eyes of 15 patients had rcH; 21 (77.77%) eyes had fibrovascular proliferation, whereas 6 (22.22%) eyes did not. the number of treated eyes was 22 (81.48%). Bilateral fibrovascular proliferation was found in 6 (40%) out of 15 patients (supplemental digital content 5; http://www.apjo.org/apjo/figure/id/7). in group B, 19 eyes of 13 patients had rcH, and none had fibrovascular proliferation. there were 8 (42.1%) treated eyes (supplemental digital content 6; http://www.apjo.org/apjo/ figure/id/8). the number of treated eyes was significantly higher in group a than in group B (P = 0.01; table 2). in group a, the fibrovascular proliferation (21 eyes) was noted in the posterior pole in 9 eyes and in the periphery in 5 eyes; 7 eyes developed both posterior pole and peripheral fibrovascular proliferation, and for statistical analysis those eyes were placed in the group with peripheral fibrovascular proliferation (table 3) . We found no statistically significant difference in the number of eyes with peripheral fibrovascular proliferation between treated and untreated eyes (P = 0.21).
in terms of treatment modalities, 17 eyes, all in group a, that developed FVP had received prior treatment. nine eyes (53%) had laser treatment only, whereas the other 8 eyes (47%) had multiple treatment modalities including laser, cryoablation, and/or vitrectomy. thirteen eyes, 5 in group a and 8 in group B, that did not develop FVP required treatment. nine eyes (69%) underwent laser treatment only, and the other 4 eyes (31%) underwent laser along with cryoablation and/or vitrectomy (table 4). this was a statistically significant difference (P = 0.045). discussion in this study, we reviewed the fundus photos of 28 patients with a confirmed diagnosis of VHl syndrome and rcH. group a comprised 15 patients, all of whom had FVP, and group B comprised 13 patients, none of which had such lesion. We noticed that fibrovascular proliferation was only seen in eyes that also had rcH. those that had bilateral rcH had a greater chance of fibrovascular proliferation. Fibrovascular proliferation was very significantly statistically associated with prior treatment of rcH (P = 0.007).
additionally, we found that peripheral fibrovascular proliferation, along with combined posterior pole and peripheral fibrovascular proliferation, can be commonly seen in these patients with VHl, especially in those with bilateral rcH. Previous reports have described the presence of fibrovascular proliferation; however, peripheral fibrovascular proliferation was rarely seen in their cases. 8, 9 one reason that we found an increased number of peripheral FVP to be more common than previously reported could be that we noted the association with prior treatment. 8, 9 We cannot tell from the prior reports how many patients had prior treatment, and we suspect that prior treatment increases the risk of developing peripheral FVP, though we can only state that there is an association because this is a retrospective study.
those that required only laser photocoagulation had a statistically significantly decreased chance of having fibrovascular proliferation. it could not be determined from this study whether this was because treatment with cryoablation and/or vitrectomy increased the risk of fibrovascular proliferation or because eyes requiring these further interventions had worse disease that required more treatment.
the fibrovascular proliferation ranged from a simple fibrovascular network (Fig. 3) to a dense fibrovascular membrane, causing significant traction at the macula (Fig. 4) , or causing tractional retinal detachment (Fig. 5) .
in 2015, Krzystolik et al 12 found extensive fibrovascular proliferation and large hemangioblastomas covered by proliferative vascularized membranes in all 24 eyes of their 23 patients undergoing pars plana vitrectomy for advanced ocular VHl because of tractional exudative retinal detachment. they also noticed the presence of significant peripheral retinal traction in all eyes. Postoperatively, the development of new rcH and FVP were among the main causes for visual deterioration in their patients. Because the new rcH developed frequently at the retinotomy site, they hypothesized that retinotomy could be an inciting factor. 12 this study suggests a relationship between treatment of rcH and occurrence of fibrovascular proliferation. although some treated eyes did not have FVP and some untreated eyes did have FVP, the number of treated eyes was significantly higher among eyes that had the lesion than in those that did not. the study was also able to provide evidence that FVP can occur in the peripheral retina much more commonly than originally believed.
limitations of this study include being a retrospective study and the small number of patients whose photos were available for analysis (28 out of 39 patients). additionally, the photographs were taken before ultrawide-field photography was available at the Mayo clinic; consequently, there may be even more cases than we found in this retrospective study. therefore, this might actually be a lower estimate of the percentage of fibrovascular proliferation. though we have shown a relationship between treatment and fibrovascular proliferation, we cannot determine that it was causative. it may be that those eyes that required treatment for their rcH also have fibrovascular proliferation. in summary, posterior pole and peripheral fibrovascular proliferation seem to be common in patients with rcH. this seems to have an association with treatment, and further studies are required to see if the present treatments may increase the risk of developing fibrovascular proliferation in VHl patients.
